The Promise of Selective PARP1 Inhibitors in Cancer Therapy
Poly-(ADP-ribose) polymerase 1 (PARP1) is a critical enzyme involved in the DNA damage response. The therapeutic inhibition of PARP1 has emerged as a promising strategy, particularly in cancers with homologous recombination deficiencies (HRDs). A recent report disclosed the discovery of (<i>S</i>)-G9 as a selective PARP1 inhibitor for clinical development.
Authors
- Steven H. Liang (ORCID: https://orcid.org/0000-0003-1413-6315)
- Taoqian Zhao
- Xin Zhou (ORCID: https://orcid.org/0000-0002-7444-462X)
- Jimmy S. Patel (ORCID: https://orcid.org/0000-0002-7322-7578)
Institutions
- Emory University (US)
Publication Details
- Journal
- ACS Medicinal Chemistry Letters
- Published
- 2025-10-08
- DOI
- https://doi.org/10.1021/acsmedchemlett.5c00561
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.05